New hope for kids with tough cancers: first test of groundbreaking cell therapy

This is a first-in-human study to test the safety and find the right dose of a new cell therapy for children and young adults whose solid tumors have returned or stopped responding to standard treatments. The therapy, called B7-H3 CAR T cells, uses a patient's own modified immune cells to target a specific protein found on many pediatric cancers. The study will enroll up to 40 participants to see if the treatment is safe and if it can help shrink tumors.